Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Shire
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Be ≥12 years of age.
Have a confirmed diagnosis of Hereditary Angioedema.
You may not be if
Receipt of any C1 inhibitor (C1 INH) therapy or any blood products for treatment or prevention of an angioedema attack within 7 days before the first dose of study drug.
Be receiving prophylactic intravenous CINRYZE that exceeds 1000 units every 3 or 4 days (maximum weekly dose 2000 units).
Have received any androgen therapy (e.g., danazol, oxandrolone, stanozolol, testosterone) within 7 days prior to the first dose of study drug.
If female, have started taking or changed the dose of any hormonal contraceptive regimen or hormone replacement therapy (i.e., estrogen/progestin containing products) within 3 months prior to the first dose of study drug.
History of allergic reaction to C1 INH products, including CINRYZE or other blood products.
History of abnormal blood clotting.
Have a known allergy to hyaluronidase or any other ingredient in the study formulation.
Clareo Health | Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks
